• Japanese
  • Korean
  • Chinese
Cover Image

World Vaccines Market 2013-2023

Vaccines and their technology - your guide to developments, opportunities, and revenues

See what the future holds for vaccines. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product, and national level to 2023.

Make sure you understand trends, R&D, opportunities, and prospects there, in human medicine, helping your research, analyses, and decisions. Discover in our work what's likely to happen for those technologies. You find there how you can benefit.

Read on to explore that industry and see what its future market could be worth.

Forecasts from 2013-2023 and other analyses show you commercial prospects

Besides revenue forecasting to 2023, our new study gives you historical data, recent results, growth rates, and market shares. There you find original analysis, with business outlooks and developments (R&D). You also get two interviews, 50 charts, and 91 tables.

Gains through understanding the vaccines sector - find advantages for your work

Leaders hold knowledge. So hear what's happening for development, production, and sales of those preventative medicines. There you see where needs and money exist, from 2013, finding how you and your organisation can prosper.

Use our predictions for vaccination, then, to help expand your business and give you more influence. Avoid falling behind there - try our new report.

So the following sections reveal what you get in that new investigation.

Revenues for the world vaccines market and submarkets

What're the secrets of that industry's progress? What's its potential? Discover in our report overall world revenue to 2023. Also find individual forecasts for four submarkets at world level:

  • Paediatric products
  • Influenza treatments
  • Adult prophylactic agents
  • Therapeutic vaccines.

How will sales rise? See, then, which product classes can generate most revenue. There you assess prospects for commercial expansion. Discover now the money-earning potential.

Explore the market for vaccinations by brand too.

Forecasts and discussions for leading products

How will leading brands perform to 2023 at world level? Our work shows you 10 individual revenue forecasts to 2023 for top products:

  • Prevnar
  • Pentacel, Pediacel, and Pentaxim
  • ProQuad, M-M-R II, and Varivax
  • RotaTeq
  • Fluzone, Panenza, Humenza, Intanza, IDflu, and Emerflu.

And also for these:

  • Gardasil
  • Infanrix and Pediarix
  • Engerix, Fendrix, Havrix, Twinrix, and Ambirix
  • Menactra and other vaccines for meningitis and pneumonia
  • Zostavax.

There you assess those agents, seeing activities, results and outlooks. You discover what's happening, understanding trends, competition, and sales prospects. Assess the future.

Our study also divides its overarching forecast into geographical regions.

Healthcare in national markets - what're the outlooks for vaccine sales?

Progress worldwide in medicine and healthcare will expand vaccination. You hear about the best revenue prospects for those preventative medicines, getting feel for national prospects.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, UK, Italy, and Spain (EU5)
  • Brazil, Russia, India, and China (BRIC).

There you assess developed and developing countries for revenues and potential sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Research and development - explore trends, possibilities, and innovations

You also investigate R&D for immune system modifiers, finding possibilities for technological and commercial advances.

In particular, our report discusses these medical technologies:

  • Paediatric agents - protecting infants and children
  • Influenza vaccines for H5N1, H1N1, and H9N2
  • Prophylactic treatments, including those for meningitis, pneumonia, TB, diphtheria, Pertussis, tetanus, and rotaviruses
  • Protectors against dengue virus, anthrax, and other forms of bio-terrorism.
  • And these, too, among others:
  • Vaccines for HIV, malaria, and bacteria
  • Prophylaxis in oncology - prostate, lung, and melanoma
  • Agents for renal, colorectal, and haematological cancers
  • Products for breast, pancreatic, ovarian, and brain cancers.

Developments for those immunological treatments hold strength, variety, and promise. See what's possible there for large pharmaceutical companies and biopharma specialists.

The rise of H7N9 influenza in 2013 shows how pandemic flu creates needs. Also, the therapeutic vaccines segment has a strong R&D pipeline. It holds over 20 late-stage candidates for solid-tumour cancers and other chronic diseases. Find promising research.

Our study explains progress in human prophylaxis, discussing issues to help your work.

Events affecting developers, producers, and sellers of vaccines

The report explains forces affecting that industry and market from 2013, including these:

  • Pro-immunisation stance in the US
  • Medical needs vying with budgetary restraints in Europe
  • Rising demand in emerging countries and under-developed regions.

And other aspects of the technology, such as these:

  • Importance of those products to the pharmaceutical industry
  • Opportunities in MRSA, HIV, and other applications
  • Delivery systems, new adjuvants, 2D barcoding, and other innovations.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market. You discover what their present and future hold.

Companies and overall 2017 market value - what predicted revenue?

What happens next? Our report predicts the world market for vaccines will reach $48bn in 2017 - with high sales growth - and expand further to 2023.

Find how high its revenues can go. Discover in our work what's possible for prophylactic medicine, and see which companies hold greatest potential.

In particular, you explore these organisations:

  • Sanofi Pasteur
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Pfizer
  • Novartis.

From 2013 to 2023 vaccines will benefit patients, payers, and companies. Our analysis predicts technological and commercial advances there. Stay ahead by using that work.

Data found nowhere else - explore vaccine development, production, and sales

In particular, then, our new investigation gives you these advantages:

  • Revenues to 2023 for vaccines at world level, 4 submarkets, and 10 products or their groups - assess prospects for investments, marketing, and sales
  • Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
  • Prospects for established competitors, rising companies, and new entrants - explore products, R&D, and outlooks for success.

World Vaccines Market 2013-2023 provides independent research and analysis. There you get competitive intelligence found only in our work, finding where the money lies. Explore progress and possibilities.

With that report you're less likely to miss knowledge and opportunity. Also find there how you could save time and gain more recognition for insight.

Ordering now lets you discover trends, predictions, and sales opportunities for vaccines

Our new report is for everyone analysing preventative medicines and related biotechnology. There you discover predictions and discussions. Avoid missing out - please order now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Overview of Findings
  • 1.2. Chapters in the Report
  • 1.3. Research and Analysis Methods
  • 1.4. What Are Vaccines?

2. Overview of Vaccines Market, 2013-2023

  • 2.1. Vaccines Market to Continue to Perform Strongly to 2023
  • 2.2. Paediatric Vaccines Remain Central to Market
    • 2.2.1. Adult Vaccination and Therapeutic Vaccines the Major Drivers to 2023
  • 2.3. What Diseases and Technologies Drive the Market in 2013?
    • 2.3.1. Ancillary Technologies
  • 2.4. Pfizer's Prevnar Leads the Market in 2013
  • 2.5. Top Three Companies Held 52% of Market in 2012
    • 2.5.1. Sanofi Pasteur: Leading Paediatric Portfolio
    • 2.5.2. GlaxoSmithKline: a Strong Presence in Every Segment
    • 2.5.3. Merck: Zostavax Revival Boosts 2012 Performance
    • 2.5.4. Pfizer: A Major Player on the Strength of Prevnar
    • 2.5.5. Novartis: Vaccines Business to be Divested?
    • 2.5.6. Other Players in the Market: A Crowded Second Tier

3. Paediatric Vaccines Segment, 2013-2023

  • 3.1. Segment to Lose Market Share, but Still Record Strong Growth
  • 3.2. Combinations Form Basis of Segment Revenues
  • 3.3. Prevnar Franchise Represents a Quarter of the Paediatric Segment's Total Value in 2012
    • 3.3.1. Prevnar-13: Domination to Continue?
      • 3.3.1.1. First of the Blockbuster Vaccines
      • 3.3.1.2. Label Extensions for Prevnar Continue
      • 3.3.1.3. Synflorix Competing Strongly in Emerging Markets
      • 3.3.1.4. Big Three Vaccine Manufacturers All Set to Challenge Pfizer in Pneumococcal Disease Area
      • 3.3.1.5. How Much Room for Growth for Prevnar-13?
    • 3.3.2. Sanofi Pasteur and GlaxoSmithKline Competing in Paediatric Combination Space
      • 3.3.2.1. Hexaxim Boosts Sanofi Portfolio
      • 3.3.2.2. GlaxoSmithKline Combinations Make Gains in US in 2012
      • 3.3.2.3. Inadequacies in Pertussis and Hepatitis B Care
      • 3.3.2.4. Room for Vaccine Competition in Those Disease Areas?
      • 3.3.2.5. Sanofi and GSK Head-to-Head, 2013-2023
    • 3.3.3. Competition Increases in Meningitis Vaccines Space
      • 3.3.3.1. Menveo Label Widened in August 2013
      • 3.3.3.2. Other Competitors for Paediatric A, C, Y and W-135Serotypes Market
      • 3.3.3.3. Bexsero Still to Convince EU Payers
    • 3.3.4. Four-Disease Combination is Merck's Leading Paediatric Vaccine
      • 3.3.4.1. Supply Issues Still Restraining ProQuad
      • 3.3.4.2. Varivax Commercial Backbone of Combination
      • 3.3.4.3. Mumps Immunity Waning?
      • 3.3.4.4. Will MMR-II/ProQuad/Varivax Realise its Full Market Potential?
    • 3.3.5. Duel for the Rotavirus Market Continues
      • 3.3.5.1. RotaTeq Leads the Market
      • 3.3.5.2. Rotavirus Immunisation Added to UK Schedules
      • 3.3.5.3. New Chinese and Indian Products Come to Developing World
      • 3.3.5.4. Will RotaTeq Hit the Blockbuster Heights?
    • 3.3.6. Paediatric Vaccines Against Other Diseases, 2013
      • 3.3.6.1. Japanese Encephalitis Vaccine Approved for Children
      • 3.3.6.2. Mosquirix Records Disappointing Phase 3Data
      • 3.3.6.3. Sanofi Records a First in 50 Years of Dengue Research
      • 3.3.6.4. Two MedImmune RSV Vaccines in Development
      • 3.3.6.5. Novartis Targeting Typhoid Opportunity
      • 3.3.6.6. Hand, Foot and Mouth Vaccine: A Chinese Target
      • 3.3.6.7. Anthrax Vaccines for Children?
      • 3.3.6.8. Potential Vaccines for Autism and Diabetes
  • 3.4. Summary: The Biggest Segment, but the Least Dynamic

4. Influenza Vaccines Segment, 2013-2023

  • 4.1. New Pandemics Offer Biggest Growth Opportunities to 2023
  • 4.2. Major Seasonal and Pandemic Vaccine Opportunities Remain
  • 4.3. Abbvie and AstraZeneca Among the Segment's Big Players
    • 4.3.1. Sanofi has the Largest Influenza Franchise
      • 4.3.1.1. Seasonal Vaccines Dominate the Franchise
      • 4.3.1.2. Quadrivalent Product Will Bolster Steady Growth for the Fluzone-Led Franchise
      • 4.3.1.3. Novartis' Portfolio Leads the Seasonal Influenza Competition
      • 4.3.1.4. GlaxoSmithKline and AstraZeneca Also Competing
      • 4.3.1.5. Merck to Join the Seasonal Market Leaders?
    • 4.3.2. Differentiating Seasonal Influenza Vaccines
      • 4.3.2.1. CDC Promises Redesign of Influenza Vaccine Coverage
      • 4.3.2.2. FDA Endorses Quadrivalents for the First Time in 2013
      • 4.3.2.3. Cell Culture and Baculovirus-Derived Products Join the Market
      • 4.3.2.4. Significant Scope for Enlarging the Patient Population
      • 4.3.2.5. VLP, VERO and Intranasal Candidates in Pipeline
    • 4.3.3. Threat and Opportunity: the Pandemic Influenza Space
      • 4.3.3.1. H5N1: The Main Target
      • 4.3.3.2. Novavax's VLP Product Among the Leading H5N1 Candidates
      • 4.3.3.3. H1N1: New Options for Post-Pandemic Strain
      • 4.3.3.4. Pandemic H9N2: A Continuous Background Risk
      • 4.3.3.5. H7N9: New Pandemic Threat in 2013
      • 4.3.3.6. Response to H7N9 Beyond China and Taiwan
    • 4.3.4. Universal Influenza Vaccines: A Distant Dream?
      • 4.3.4.1. Universal Candidates Reach Phase 2
  • 4.4. Overview: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed

5. Adult Prophylactic Vaccines Segment, 2013-2023

  • 5.1. Prevnar Approval to Boost the Segment to 2023
  • 5.2. Routine Adult Vaccination to Become a Reality by 2023?
  • 5.3. Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
    • 5.3.1. Gardasil Dominating HPV Disease Area
      • 5.3.1.1. Cervarix Declines as Japan Catches Up in 2012
      • 5.3.1.2. New Markets for Gardasil
      • 5.3.1.3. Is There a Need for V503?
      • 5.3.1.4. GlaxoSmithKline and Merck to Continue Dominating this Space
      • 5.3.1.5. Gardasil's Prospects Depend on its Successor
    • 5.3.2. GlaxoSmithKline Continues to Dominate Hepatitis Vaccine Space
      • 5.3.2.1. Few Competitors Besides Merck's Recombivax
      • 5.3.2.2. China Market Key for GlaxoSmithKline's Hepatitis Vaccines
      • 5.3.2.3. FDA Rejects Dynavax's Heplisav Citing Safety Concerns
      • 5.3.2.4. Hepatitis C A Major Pipeline Target
      • 5.3.2.5. Engerix and Other GlaxoSmithKline Products to Continue Growing Through 2017
    • 5.3.3. Reimmunisation against Pneumococcal, Meningococcal Disease
      • 5.3.3.1. Menveo and Nimenrix Sanofi's Main Challengers
      • 5.3.3.2. Pfizer and JN-International Have Pipeline Candidates
      • 5.3.3.3. How Big is the Adult Pneumonia Potential Market?
      • 5.3.3.4. Sanofi Leads Booster Vaccination Space
      • 5.3.3.5. Pertussis and TB Major Unaddressed Needs
    • 5.3.4. Shingles Market Remains Relatively Untapped
      • 5.3.4.1. Will Zostavax's Revival Continue?
      • 5.3.4.2. Two New Late-Stage Shingles Candidates
      • 5.3.4.3. Other Herpesvirus R&D in Vaccines
      • 5.3.4.4. Need for Cytomegalovirus Vaccine?
    • 5.3.5. Other Unmet Needs in the Adult Segment
      • 5.3.5.1. Dengue Fever the Next Target
      • 5.3.5.2. Anthrax and Other Bio-Terror Vaccines
      • 5.3.5.3. HIV Vaccine: 30-Year Hunt Continues After HVTN 505
      • 5.3.5.4. Developers' Interest in Malaria
      • 5.3.5.5. Anti-Staphyloccocal Vaccines Form an Important Need
      • 5.3.5.6. Other New Antibacterial Vaccines in Development
      • 5.3.5.7. Important New Antiviral Vaccine Targets
      • 5.3.5.8. Protozoans and Other Vaccine Targets
  • 5.4. Overview: Extensive Pipeline, but Adult Immunisation Still Needs to Become More Widely Established

6. Therapeutic Vaccines Segment, 2013-2023

  • 6.1. The Fastest-Growing Segment to 2023
  • 6.2. The Future for Vaccines R&D?
  • 6.3. Anti-Allergy Vaccines Make Up Bulk of Segment in 2012
    • 6.3.1. Provenge: Troubled Segment Leader
      • 6.3.1.1. Competition and Patient Doubt Undermine Provenge
      • 6.3.1.2. Future Sales Growth for Dendreon?
      • 6.3.1.3. Two Phase 3 Allogeneic Vaccines to Provide Competition
      • 6.3.1.4. NorthWest Biotherapeutics Following Oxford BioMedica Out of the Race?
      • 6.3.1.5. Products in Development in Ten Areas of Oncology
    • 6.3.2. Novarx Heads Lung Cancer Hunt After Failure of Stimuvax
      • 6.3.2.1. Lucanix Leads the Way
      • 6.3.2.2. MAGE-A3 Also in Late-Stage Trials
      • 6.3.2.3. Stiff Competition for MAGE-A3 in Melanoma Pipeline
      • 6.3.2.4. Agenus In Late-Stage Trials in Melanoma and Renal Cancer
    • 6.3.3. Other Major Solid Tumour Targets
      • 6.3.3.1. Breast Cancer One of the Most-Crowded Areas of Therapeutic Vaccines Pipeline
      • 6.3.3.2. Pancreatic Cancer: Major Unmet Need, Slender Pipeline
      • 6.3.3.3. Still Several Ovarian Cancer Candidates After Abagovamab Disappointment
      • 6.3.3.4. Several Candidates Against Glioblastoma
      • 6.3.3.5. Other Cancer Vaccines in Development
    • 6.3.4. Other Chronic Diseases: Vaccine Treatments for RA and Diabetes?
      • 6.3.4.1. New Options in Chronic Neurodegenerative Diseases Pipeline
      • 6.3.4.2. HIV: Major Therapeutic Vaccines Target
      • 6.3.4.3. Other Chronic Viral Infections Pipeline
      • 6.3.4.4. Cat Allergies and Other New Allergy Targets for Vaccine R&D
      • 6.3.4.5. Addictions and Other Therapeutic Vaccine Targets
  • 6.4. Overview: Huge Potential, but Little Market Success to Date

7. Leading National Vaccines Markets, 2013-2023

  • 7.1. US and EU5 Represent Over 70% of Market
  • 7.2. The US Remains the Foundation of the Global Market in 2013
  • 7.3. Strong Pro-Immunisation Stance in US
  • 7.4. EU5 Medical Need Vies with Austerity Economics
  • 7.5. Japan: Low Existing Coverage Means High Market Potential
  • 7.6. BRIC Nations: To Overtake EU5 in Market Share by 2023
  • 7.7. Rest of the World: Unmet Needs Remain

8. Qualitative Industry Analysis, 2013

  • 8.1. Vaccines Expand in Importance for Pharmaceutical Industry
  • 8.2. Weaknesses: Many Challenges in this Sector
  • 8.3. Opportunities: MRSA, HIV, and Other Unmet Needs Remain
  • 8.4. Threats: Cost-Effectiveness a Harder Sell for Governments
  • 8.5. Social Concerns: One of the Most Emotive Areas of Healthcare
  • 8.6. Technological Developments: New Delivery Systems, New Adjuvants, 2D Barcoding and Other Innovations
  • 8.7. Health Economics: 2700% Increase in Cost of Vaccinating a Child
  • 8.8. Political Issues: From Bio-Defence to Polio Eradication, Governments Hold the Key to the Market

9. Research Interviews, 2013

  • 9.1. Interview with Dr. Louis J. Picker, Oregon Health and Science University
    • 9.1.1. Challenges of DNA/Ad Vector Vaccines
    • 9.1.2. Broadly Neutralising Antibodies for HIV
    • 9.1.3. A Third Way? The T-Cell Vaccine Approach
    • 9.1.4. Combinations and Other Strategies for HIV
    • 9.1.5. Getting to the Clinic with Therapeutic and Prophylactic HIV Vaccines
  • 9.2. Interview with Tamar Ben-Yedidia, PhD, Chief Scientific Officer, and Tanya Gottlieb, PhD, Business Development, BiondVax Pharmaceuticals
    • 9.2.1. Progress of BiondVax's Candidate Vaccine
    • 9.2.2. Trialling the Vaccine as a Primer
    • 9.2.3. Assays for Universal Vaccine Effectiveness
    • 9.2.4. Key Differentiators for BiondVax's Candidate

10. Conclusions

  • 10.1. Vaccines Market Remains on Course for Steady Growth to 201
  • 10.2. Sales Growth to Be Sustained 2018-2023
  • 10.3. Adult Segment to Grow Twice as Fast as Paediatric Segment
  • 10.4. Therapeutic Vaccines to Gain Importance from 2018-2023
  • 10.5. Market Remains Heavily Consolidated
  • 10.6. Blockbuster Products Lead the Way; Scope in Developing World
  • 10.7. Rich Pipeline, Particularly in Therapeutic Vaccines
  • 10.8. Concluding Remarks

List of Tables

  • Table 1.1: Currency Exchange Rates
  • Table 2.1: Vaccines Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 2.2: Vaccines Market: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 2.3: Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
  • Table 2.4: Vaccines Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
  • Table 2.5: Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
  • Table 2.6: Vaccines Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023
  • Table 2.7: Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
  • Table 2.8: Vaccine-Preventable Diseases and their Statistics
  • Table 2.9: Types of Vaccine, 2013
  • Table 2.10: Leading Vaccine Products: Revenues ($m), Market Shares (%), 2012
  • Table 2.11: Leading Vaccine Products: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
  • Table 2.12: Leading Vaccine Products: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023
  • Table 2.13: Leading Vaccine Manufacturers: Revenues ($m), Market Share (%), 2012
  • Table 3.1: Paediatric Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 3.2: Paediatric Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 3.3: Leading Paediatric Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Table 3.4: Selected Pipeline Products in Paediatric Vaccines Segment, 2013
  • Table 3.5: Paediatric Pneumococcal Vaccines Pipeline, 2013
  • Table 3.6: Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic): Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 3.7: Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic): Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 3.8: Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 3.9: Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 3.10: ProQuad/ MMR-II/ Varivax: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 3.11: ProQuad/ MMR-II/ Varivax: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 3.12: RotaTeq: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 3.13: RotaTeq: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 4.1: Influenza Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 4.2: Influenza Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 4.3: Leading Influenza Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Table 4.4: Selected Pipeline Products in Influenza Vaccines Segment, 2013
  • Table 4.5: Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 4.6: Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 4.7: Selected Pipeline Seasonal Influenza Vaccine Products, 2013
  • Table 4.8: Selected Pipeline H5N1 Pandemic Vaccine Products, 2013
  • Table 4.9: Selected Pipeline H1N1 Pandemic Vaccine Products, 2013
  • Table 4.10: Selected Pipeline H9N2 Pandemic Vaccine Products, 2013
  • Table 4.11: Selected Pipeline Universal Influenza Vaccine Products, 2013
  • Table 5.1: Adult Prophylactic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 5.2: Adult Prophylactic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.3: Leading Adult Prophylactic Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Table 5.4: Selected Pipeline Products in Adult Prophylactic Vaccines Segment, 2013
  • Table 5.5: Gardasil: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 5.6: Gardasil: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.7: Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 5.8: Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.9: Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 5.10: Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.11: Selected Pipeline Meningitis Vaccines, 2013
  • Table 5.12: Selected Pipeline Pneumonia Vaccines, 2013
  • Table 5.13: Selected Pipeline TB, Diphtheria, Pertussis, Tetanus and Rotavirus Adult Vaccines, 2013
  • Table 5.14: Zostavax: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 5.15: Zostavax: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 5.16: Selected Pipeline for Herpesvirus Vaccines, 2013
  • Table 5.17: Selected Pipeline for New Adult Vaccines for Currently Vaccine-Preventable Diseases, 2013
  • Table 5.18: Selected Pipeline for Dengue Virus Vaccines, 2013
  • Table 5.19: Selected Pipeline for Anthrax and Other Potential Bio-Terrorism Agents Vaccines, 2013
  • Table 5.20: Selected Pipeline for HIV Vaccines, 2013
  • Table 5.21: Selected Pipeline for Malaria Vaccines, 2013
  • Table 5.22: Selected Pipeline for New Antibacterial Vaccines, 2013
  • Table 5.23: Selected Pipeline for New Antiviral Vaccines, 2013
  • Table 5.24: Selected Pipeline for Other New Adult Prophylactic Vaccines, 2013
  • Table 6.1: Therapeutic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
  • Table 6.2: Therapeutic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
  • Table 6.3: Leading Therapeutic Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Table 6.4: Selected Therapeutic Vaccines, 2013
  • Table 6.5: Selected Pipeline Prostate Cancer Therapeutic Vaccines, 2013
  • Table 6.6: Selected Pipeline Lung Cancer Therapeutic Vaccines, 2013
  • Table 6.7: Selected Pipeline Melanoma Therapeutic Vaccines, 2013
  • Table 6.8: Selected Pipeline Renal Cancer Therapeutic Vaccines, 2013
  • Table 6.9: Selected Pipeline Colorectal Cancer Therapeutic Vaccines, 2013
  • Table 6.10: Selected Pipeline Haematological Cancer Therapeutic Vaccines, 2013
  • Table 6.11: Selected Pipeline Breast Cancer Therapeutic Vaccines, 2013
  • Table 6.12: Selected Pipeline Pancreatic Cancer Therapeutic Vaccines, 2013
  • Table 6.13: Selected Pipeline Ovarian Cancer Therapeutic Vaccines, 2013
  • Table 6.14: Selected Pipeline Brain Cancer Therapeutic Vaccines, 2013
  • Table 6.15: Selected Other Cancer Therapeutic Vaccines, 2013
  • Table 6.16: Selected RA and Diabetes Therapeutic Vaccines, 2013
  • Table 6.17: Selected AD and MS Therapeutic Vaccines, 2013
  • Table 6.18: Selected HIV Therapeutic Vaccines, 2013
  • Table 6.19: Selected Other Chronic Viral Infections Therapeutic Vaccines, 2013
  • Table 6.20: Selected Anti-Allergy Therapeutic Vaccines, 2013
  • Table 6.21: Selected Other Therapeutic Vaccines, 2013
  • Table 7.1: Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2012
  • Table 7.2: Vaccines Market by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
  • Table 7.3: Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2017
  • Table 7.4: Vaccines Market by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023
  • Table 7.5: Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2023
  • Table 8.1: World Vaccines Market: Strengths and Weaknesses, 2013
  • Table 8.2: World Vaccines Market: Opportunities and Threats, 2013
  • Table 8.3: World Vaccines Market: STEP Analysis, 2013-2023

List of Figures

  • Figure 2.1: Vaccines Market: Revenues ($m), 2012-2023
  • Figure 2.2: Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
  • Figure 2.3: Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
  • Figure 2.4: Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
  • Figure 2.5: Vaccines Market Breakdown by Segment: Revenues ($m), 2012-2023
  • Figure 2.6: Vaccines Market Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
  • Figure 2.7: Leading Vaccine Products: Revenues ($m), Market Share (%), 2012
  • Figure 2.8: Leading Vaccine Products: Revenues ($m), 2012-2023
  • Figure 2.9: Leading Vaccine Manufacturers: Revenues ($m), Market Share (%), 2012
  • Figure 3.1: Paediatric Vaccines Segment: Revenues ($m), 2012-2023
  • Figure 3.2: Global Mortality Due to VPDs in Children Under Five, Breakdown by Disease (%), 2008
  • Figure 3.3: Leading Paediatric Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Figure 3.4: Leading Paediatric Pneumococcal Vaccine Products: Market Share (%), 2012
  • Figure 3.5: Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic): Revenues ($m), 2012-2023
  • Figure 3.6: Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), 2012-2023
  • Figure 3.7: ProQuad/ MMR-II/ Varivax: Revenues ($m), 2012-2023
  • Figure 3.8: Division of Rotavirus Vaccine Market (%), 2012
  • Figure 3.9: RotaTeq: Revenues ($m), 2012-2023
  • Figure 3.10: Drivers and Restraints for Paediatric Vaccines, 2013
  • Figure 4.1: Influenza Vaccines Segment: Revenues ($m), 2012-2023
  • Figure 4.2: Leading Influenza Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Figure 4.3Fluzone/Panenza/Humenza/Intanza/ IDflu/Emerflu/Others: Breakdown by Seasonal and Pandemic Revenues ($m), 2010-2012
  • Figure 4.4: Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), 2012-2023
  • Figure 4.5: Drivers and Restraints for Influenza Vaccines, 2013
  • Figure 5.1: Adult Prophylactic Vaccines Segment: Revenues ($m), 2012-2023
  • Figure 5.2: Leading Adult Prophylactic Vaccine Products: Revenues ($m), Segment Market Share (%), 2012
  • Figure 5.3: Division of HPV Vaccine Market (%), 2012
  • Figure 5.4: Gardasil: Revenues ($m), 2012-2023
  • Figure 5.5: Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), 2012-2023
  • Figure 5.6: Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), 2012-2023
  • Figure 5.7: Zostavax: Revenues ($m), 2012-2023
  • Figure 5.8: Drivers and Restraints for Adult Prophylactic Vaccines, 2013
  • Figure 6.1: Therapeutic Vaccines Segment: Revenues ($m), 2012-2023
  • Figure 6.2: Leading Therapeutic Vaccine Products: Revenues ($m), Segment Market Shares (%), 2012
  • Figure 6.3: Drivers and Restraints for Therapeutic Vaccines, 2013
  • Figure 7.1: Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2012
  • Figure 7.2: Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2017
  • Figure 7.3: Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2023
  • Figure 7.4: Vaccines Market Breakdown by Region: Revenues ($m), 2012-2023
  • Figure 7.5: Vaccines Market Breakdown by Regional Bloc: Revenues ($m), 2012-2023
  • Figure 7.6: Vaccines Market Breakdown by Region: Revenues ($m), 2012, 2017, 2023
  • Figure 7.7: US Vaccines Market: Revenues ($m), 2012-2023
  • Figure 7.8: EU5 Vaccines Market: Revenues ($m), 2012-2023
  • Figure 7.9: Japanese Vaccines Market: Revenues ($m), 2012-2023
  • Figure 7.10: BRIC Nations Vaccines Market: Revenues ($m), 2012-2023
  • Figure 7.11: Rest of the World Vaccines Market: Revenues ($m), 2012-2023
  • Figure 10.1: World Vaccines Market: Revenues ($m), 2012-2017
  • Figure 10.2: World Vaccines Market: Revenues ($m), 2018-2023
  • Figure 10.3: World Vaccines Market, Breakdown by Segment: Revenues ($m), 2012-2017
  • Figure 10.4: World Vaccines Market, Breakdown by Segment: Revenues ($m), 2018-2023

Companies Listed

  • Aaron Diamond AIDS Research Center
  • Abbott Laboratories
  • AbbVie
  • Acambis
  • ACE Biosciences
  • Activartis Biotech
  • Adamis Pharmaceuticals
  • Aduro BioTech
  • Advaxis
  • Aeras
  • Aeras Global TB Vaccine Foundation
  • Affiris
  • Agency for Science, Technology and Research (Singapore)
  • Agenus
  • Akela Pharma
  • ALK Abello
  • Allergy Therapeutics
  • Allertein Therapeutics
  • Alnylam
  • AlphaVax
  • Altravax
  • American Academy of Pediatrics
  • Amgen
  • Antigen Discovery
  • Antigen Express
  • Antigenics
  • Argos Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Augmenta Biologicals
  • AuRx
  • AVAX Technologies
  • Baxter Healthcare
  • Bayer HealthCare
  • Bayhill Therapeutics
  • Beijing Key Yuan Xinhai Pharmaceutical
  • Beijing Vigoo Biological
  • Bellicum Pharmaceuticals
  • Bharat Biotech
  • Biken Japan
  • Bill & Melinda Gates Foundation
  • Bio-Manguinhos
  • BiondVax
  • Bionor Pharma
  • BioNTech
  • BioSante Pharmaceuticals
  • Biotech Synergy
  • Biovest International
  • BN ImmunoTherapeutics (Bavarian Nordic)
  • Boston Children's Hospital
  • BravoBio
  • Butantan
  • Cadila Pharma
  • Cancer Advances
  • Celldex Therapeutics
  • CEL-SCI
  • Celtic Pharma
  • Center of Molecular Immunology (Cuba)
  • Centers for Disease Control (CDC)
  • CG Therapeutics
  • Chemo-Sero-Therapeutic Research Institute
  • Chengdu Institute
  • China National Biotech Group (CNBG)
  • China NT Pharma Group
  • Chinese Centre for Disease Control
  • Chinese State Food and Drug Administration (SFDA)
  • Chiron
  • Circassia
  • Colby Pharmaceutical
  • Columbia University
  • Cosmo Pharmaceuticals
  • Crucell
  • CSL Biotherapies
  • Cuba's Center of Molecular Immunology
  • CureVac
  • Cytokine PharmaSciences
  • Cytos Biotechnology
  • Daiichi Sankyo
  • DBV Technologies
  • Dendreon
  • Denka Seiken Company
  • Desmond Tutu TB Centre
  • Diabetes UK
  • Diamyd
  • Dynavax
  • DynPort Vaccine Company
  • Eisai
  • Elea Laboratories
  • EMD Serono
  • Emergent BioSolutions
  • Endocyte
  • Epeius Biotechnologies
  • Erasmus Medical Centre
  • Etubics
  • European Medicines Agency (EMA)
  • Evans Medical
  • Food and Drug Administration (US FDA)
  • Galena Biopharma
  • GAVI Alliance
  • GE Healthcare
  • GeneCure Biotechnologies
  • Genetic Immunity
  • Genocea Biosciences
  • GenPhar
  • GenVec
  • GeoVax Labs
  • Geron
  • GlaxoSmithKline (GSK)
  • Glide Pharma
  • Gliknik
  • Global Health Innovative Technology Fund (GHIT Fund)
  • GlobeImmune
  • Gradalis
  • Greer Laboratories
  • Hawaii Biotech
  • Health Protection Agency (HPA)
  • Heat Biologics
  • Helmholtz Centre for Infection Research
  • iBio
  • Ichor Medical Systems
  • immatics biotechnologies
  • Immune Response Biopharma
  • Immune Targeting Systems
  • Immunitor
  • ImmunoCellular Therapeutics
  • Immunocore
  • ImmunoFrontier
  • Immunomic Therapeutics
  • Immunotope
  • Immunovaccine
  • Immunovative Therapies
  • ImmusanT
  • Infectious Diseases Research Institute
  • Inovio Pharmaceuticals
  • Intercell
  • Intercell USA
  • International AIDS Vaccine Initiative (IAVI)
  • International Federation of Pharma Manufacturers and Associations (IFPMA)
  • International Medica Foundation
  • Inviragen
  • J. Craig Venter Institute
  • Janssen Alzheimer Immunotherapy
  • JN-International Medical
  • Johnson & Johnson
  • Joint Committee on Vaccination and Immunisation (JCVI, UK)
  • KAEL-GemVax
  • Karolinska Institute
  • Kitasato Institute
  • Korean Ministry of Health and Welfare
  • La Jolla Institute for Allergy & Immunology
  • Life Technologies
  • LigoCyte Pharmaceuticals
  • Liquidia Technologies
  • London School of Hygiene and Tropical Medicine
  • MabVax Therapeutics
  • Max Planck Society
  • MaxCyte
  • Medecins Sans Frontieres (MSF)
  • Medicago
  • MedImmune
  • Memgen
  • Menarini
  • Merck & Co.
  • Merck Serono
  • Meridian Biosciences
  • Mitsubishi Tanabe Pharma
  • Momotaro-Gene
  • Nabi Biopharmaceuticals
  • NanoBio
  • Nanotherapeutics
  • National Administration of Medicines, Food and Medical Technology (ANMAT, Argentina)
  • Natrix Separations
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novadigm Therapeutics
  • Novartis
  • NovaRx
  • Novavax
  • Novo Energies
  • Nuron Biotech
  • NuVax Therapeutics
  • Nypro Healthcare
  • Okairos
  • OncoPep
  • Oncothyreon
  • Opal Therapeutics
  • Opexa Therapeutics
  • Opko Health
  • Optimer Pharmaceuticals
  • Orban Biotech
  • Oxford BioMedica
  • PaxVax
  • Petrovax
  • Pfizer
  • PharmAthene
  • Pique Therapeutics
  • Polynoma
  • Prima Biomed
  • Profectus Biosciences
  • Progenics Pharmaceuticals
  • Protein Sciences
  • PsiOxus Therapeutics
  • Quantum Immunologics
  • Quest PharmaTech
  • Sanaria
  • Sanofi
  • Sanofi Pasteur
  • Sarepta
  • SciVac
  • Scripps Research Institute
  • Selecta Biosciences
  • Serum Institute of India
  • Shanghai BravoBio
  • Shanghai Pharma
  • Shantha Biotech
  • Shionogi
  • Sinopharm Group
  • Sinovac Biotech
  • Soligenix
  • South African Tuberculosis Vaccine Initiative (SATVI)
  • Stallergenes
  • Stemline Therapeutics
  • Sumagen
  • Sunovion Pharmaceuticals
  • Takeda
  • TapImmune
  • TD Vaccines
  • Tekmira
  • Tesco
  • Tetragenetics
  • Teva Pharmaceutical industries
  • Theraclone Sciences
  • Thymon
  • Topaz Pharmaceuticals
  • Transgene
  • TVAX Biomedical
  • UK Joint Committee on Vaccination and Immunisation
  • UMN Pharma
  • UNICEF
  • United Biomedical
  • Universidad de Chile
  • Université Laval
  • University of Cape Town
  • University of Guelph
  • University of London
  • University of Minnesota's Centre for Infectious Disease Research and Policy
  • University of Queensland
  • University of Toronto
  • US National Biodefence Science Board
  • US Naval Medical Research Center
  • Utrecht University
  • Vaccine Research Center (NIAID)
  • Vaccine Technologies
  • Vaccinogen
  • Vakzine Projekt Management
  • Valneva
  • Vanderbilt University
  • Vaxart
  • Vaxin
  • VaxInnate
  • VaxOnco
  • Vical
  • Vivalis
  • Vodafone
  • Walter Reed Army Institute
  • World Health Organisation (WHO)
  • Xcellerex
  • Zhejiang Tianyuan
  • Zuellig Pharma
Show More
Pricing